{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:28:49Z","timestamp":1793806129825,"version":"4.6.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Selective \u03b21-blockers are fundamental in managing hypertension, coronary artery disease, and heart failure. Yet, despite their widespread use, practical guidance on safe and individualized prescribing remains limited. Existing evidence is largely derived from controlled clinical trials, which may not fully capture drug-specific adverse events, sex-related susceptibility, or early-onset risks observed in routine clinical practice. To generate real-world, evidence-based recommendations for the safe use of selective \u03b21-blockers, we compared the adverse event profiles of metoprolol, bisoprolol, and atenolol using 2 large pharmacovigilance systems. Adverse drug events reported for the 3 agents between 2004 and Q2 2025 were retrieved from the US Food and Drug Administration Adverse Event Reporting System, a spontaneous-reporting system, and compared with reports from the Canadian Vigilance Adverse Reaction Online Database. Disproportionality analyses, preferred term mapping, exploratory sex-stratified comparisons, and time-to-onset modeling were conducted to characterize shared reporting patterns, drug-specific signals, and potential patient-level modifiers. Across all 3 agents, disproportionate reporting was observed for a common cardiovascular spectrum that included bradycardia, conduction abnormalities, heart failure, and blood pressure instability. Metoprolol showed prominent reporting signals for BRASH syndrome and neuropsychiatric and suicide-related events. Bisoprolol showed signals for bradyarrhythmia, hyperkalemia, and acute kidney injury. Atenolol showed reporting patterns involving blood pressure perturbations, electrolyte imbalance, and interaction-related events. Exploratory sex-stratified analyses identified differences in the reporting distributions of several PT = preferred terms for metoprolol and atenolol, whereas bisoprolol showed a more balanced distribution. All 3 agents displayed early-failure time-to-onset patterns, supporting closer monitoring after treatment initiation. This real-world pharmacovigilance assessment identifies drug-specific patterns of disproportionate reporting that may inform hypothesis generation and individualized monitoring. Because spontaneous-reporting data cannot establish incidence or causality, the findings should complement, rather than replace, clinical judgment and confirmation in controlled or longitudinal data sources.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050763","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:01:55Z","timestamp":1790359315000},"page":"e50763","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative real-world safety profiles of selective \u03b21-adrenergic receptor blockers"],"prefix":"10.1097","volume":"105","author":[{"given":"Weijie","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Cardiology, Affiliated Hospital of Shanxi University of Chinese Medicine, Shanxi University of Chinese Medicine, Taiyuan, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haosen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Affiliated Hospital of Shanxi University of Chinese Medicine, Shanxi University of Chinese Medicine, Taiyuan, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Affiliated Hospital of Shanxi University of Chinese Medicine, Shanxi University of Chinese Medicine, Taiyuan, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Integrative Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelong","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Integrative Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiling","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Integrative Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Integrative Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zezhou","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, PKUCare CNOOC Hospital, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9015-4096","authenticated-orcid":false,"given":"Peili","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Integrative Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.jacc.2025.08.015","article-title":"Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023.","volume":"86","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1755-5922.2011.00306.x","article-title":"Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity.","volume":"31","author":"Ladage","year":"2013","journal-title":"Cardiovasc Ther"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1573402114666180918102735","article-title":"Three generations of \u03b2-blockers: history, class differences and clinical applicability.","volume":"15","author":"do Vale","year":"2019","journal-title":"Curr Hypertens Rev"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(23)01733-6","article-title":"\u03b2 blockers switched to first-line therapy in hypertension.","volume":"402","author":"Messerli","year":"2023","journal-title":"Lancet"},{"key":"R5-20261104","first-page":"95","article-title":"A multicentre observational study on landiolol use, efficacy, and safety in european patients with supraventricular arrhythmia (Landi-UP).","volume":"15","author":"Dizdarevic","year":"2026","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","article-title":"Beta-blockers after myocardial infarction and preserved ejection fraction.","volume":"390","author":"Yndigegn","year":"2024","journal-title":"N Engl J Med"},{"key":"R7-20261104","first-page":"e8236","article-title":"Metoprolol-associated central nervous system complications.","volume":"12","author":"Shah","year":"2020","journal-title":"Cureus"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s10557-021-07205-y","article-title":"Therapeutic properties of highly selective \u03b2-blockers with or without additional vasodilator properties: focus on bisoprolol and nebivolol in patients with cardiovascular disease.","volume":"36","author":"AlHabeeb","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00003495-198223030-00002","article-title":"Beta-blockers and renal function.","volume":"23","author":"Wilkinson","year":"1982","journal-title":"Drugs"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"24918","DOI":"10.1038\/s41598-025-09617-4","article-title":"CYP2D6-inhibiting drugs and risk of fall injury after newly initiated therapy with beta-blockers-a register-based case-crossover study.","volume":"15","author":"Leander","year":"2025","journal-title":"Sci Rep"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3390\/jpm12060870","article-title":"Sex-based difference in the effect of metoprolol on heart rate and bradycardia in a population-based setting.","volume":"12","author":"Hendriksen","year":"2022","journal-title":"J Pers Med"},{"key":"R12-20261104","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s12672-025-02502-6","article-title":"Drug-induced second tumors: a disproportionality analysis of the FAERS database.","volume":"16","author":"Chen","year":"2025","journal-title":"Discov Oncol"},{"key":"R13-20261104","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s11096-025-01943-x","article-title":"Psychiatric adverse events linked to glucagon-like peptide 1 analogues: a disproportionality analysis in American, Canadian and Australian adverse event databases.","volume":"47","author":"Katranski","year":"2025","journal-title":"Int J Clin Pharm"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio.","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R15-20261104","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R16-20261104","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R17-20261104","first-page":"18","article-title":"When not to use beta-blockers in seniors with hypertension.","volume":"57","author":"Schumann","year":"2008","journal-title":"J Fam Pract"},{"key":"R18-20261104","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41440-024-01894-2","article-title":"Risk of developing hyperkalemia in patients with hypertension treated with combination antihypertensive therapy - a retrospective register-based study.","volume":"48","author":"Al-Janabi","year":"2025","journal-title":"Hypertens Res"},{"key":"R19-20261104","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ejhf.13","article-title":"Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction.","volume":"16","author":"Clark","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"R20-20261104","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/clpt.1980.166","article-title":"Atenolol kinetics in renal failure.","volume":"28","author":"McAinsh","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"R21-20261104","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000169030","article-title":"Hypocalcemia, morbidity, and mortality in end-stage renal disease.","volume":"16","author":"Foley","year":"1996","journal-title":"Am J Nephrol"},{"key":"R22-20261104","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jchf.2020.12.011","article-title":"Sex differences in clinical course and patient-reported outcomes among patients hospitalized for heart failure.","volume":"9","author":"Blumer","year":"2021","journal-title":"JACC Heart Fail"},{"key":"R23-20261104","doi-asserted-by":"crossref","first-page":"117269","DOI":"10.1016\/j.atherosclerosis.2023.117269","article-title":"Sex-specific differences in cardiovascular risk factors and implications for cardiovascular disease prevention in women.","volume":"384","author":"Rajendran","year":"2023","journal-title":"Atherosclerosis"},{"key":"R24-20261104","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/jpm12060907","article-title":"Sex-related differences in pharmacological response to CNS drugs: a narrative review.","volume":"12","author":"Romanescu","year":"2022","journal-title":"J Pers Med"},{"key":"R25-20261104","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1093\/eurheartj\/ehv161","article-title":"Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC.","volume":"36","author":"Rosano","year":"2015","journal-title":"Eur Heart J"},{"key":"R26-20261104","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/ejhf.3401","article-title":"Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: size matters.","volume":"26","author":"de la Espriella","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"R27-20261104","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/s41583-021-00513-0","article-title":"Sex differences in anxiety and depression: circuits and mechanisms.","volume":"22","author":"Bangasser","year":"2021","journal-title":"Nat Rev Neurosci"},{"key":"R28-20261104","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.amjmed.2021.04.007","article-title":"Risk of electrolyte disorders, syncope, and falls in patients taking thiazide diuretics: results of a cross-sectional study.","volume":"134","author":"Ravioli","year":"2021","journal-title":"Am J Med"},{"key":"R29-20261104","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ecl.2021.03.009","article-title":"Postmenopausal osteoporosis: latest guidelines.","volume":"50","author":"Arceo-Mendoza","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R30-20261104","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41467-025-56217-x","article-title":"Testosterone exacerbates neutrophilia and cardiac injury in myocardial infarction via actions in bone marrow.","volume":"16","author":"Svedlund Eriksson","year":"2025","journal-title":"Nat Commun"},{"key":"R31-20261104","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41467-023-37579-6","article-title":"Associations between mental health, blood pressure and the development of hypertension.","volume":"14","author":"Schaare","year":"2023","journal-title":"Nat Commun"},{"key":"R32-20261104","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jacc.2005.06.052","article-title":"Hyperdynamic myocardial response to beta-adrenergic stimulation in patients with chest pain and normal coronary arteries.","volume":"46","author":"Madaric","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R33-20261104","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","article-title":"2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy.","volume":"42","author":"Glikson","year":"2021","journal-title":"Eur Heart J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:01:11Z","timestamp":1793804471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050763"}},"subtitle":["A multi-database pharmacovigilance disproportionality study"],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":33,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050763","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2025-11-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}